Brief: Jazz Pharmaceuticals Upon Termination Of Deal Chimerix Will Be Required To Pay Termination Fee Of $35 Million In Cash
05/03/2025 12:50
March 5 (Reuters) - Chimerix Inc CMRX.O: JAZZ PHARMACEUTICALS:UPON TERMINATION OF DEAL UNDER SPECIFIED CIRCUMSTANCES, CHIMERIX WILL BE REQUIRED TO PAY CO TERMINATION FEE OF $35 MILLION IN CASH Source text: [ID:n0001193125-25-046226] Further company coverage: CMRX.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Jazz Pharmaceuticals
See all newsBrief: Jazz Pharmaceuticals Enters Amendment No. 4 To Credit Agreement On Sept 23, 2026
U.S. STOCKS ON THE MOVE-BWX Technologies, Synopsys,Burlington Stores
U.S. STOCKS ON THE MOVE-Jazz Pharmaceuticals, Celularity, Infleqtion
Jazz Pharma dips after upsized $1.1 bln convertible offering
Brief: Jazz Pharmaceuticals Announces Private Offering Of $1.0 Billion Of Exchangeable Senior Notes Due 2032